Idera Pharmaceuticals, Inc.
(NASDAQ : IDRA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Loading IDRA News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-3.48%80.471.8%$677.67m
BIIBBiogen Inc.
-4.02%229.021.0%$525.14m
CELGCelgene Corporation
-4.34%96.291.2%$438.11m
AMGNAmgen Inc.
-3.82%146.451.0%$388.51m
ANACAnacor Pharmaceuticals, Inc.
-0.14%99.0615.2%$320.35m
REGNRegeneron Pharmaceuticals, Inc.
-4.95%339.483.1%$301.85m
ALXNAlexion Pharmaceuticals, Inc.
-8.56%112.992.5%$274.13m
ILMNIllumina, Inc.
-5.24%138.914.9%$155.27m
VRTXVertex Pharmaceuticals Incorporated
-7.14%81.902.6%$124.14m
MDVNMedivation, Inc.
-3.90%56.952.8%$120.74m
BMRNBioMarin Pharmaceutical Inc.
-7.94%77.014.0%$117.35m
SRPTSarepta Therapeutics, Inc.
3.58%18.5249.4%$116.18m
CPXXCelator Pharmaceuticals, Inc.
0.13%30.198.5%$107.30m
AAgilent Technologies, Inc.
-5.48%44.121.0%$94.74m
IONSIonis Pharmaceuticals, Inc.
-6.91%21.978.6%$94.46m

Company Profile

Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which is engaged in discovery, development and commercialization of novel nucleic acid therapeutics to treat patients with serious and life-threatening diseases. Idera's immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while its third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal and James B. Wyngaarden in May 25, 1989 and is headquartered in Cambridge, MA.